|
1. Scichilone N et al. Lung penetration and patient adherence considerations in the management of asthma: role of extrafine formulations. J Asthma Allergy. 2013;6:11-21. 2. Müller V et al. Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation. BMC Pulm Med 2011;11:40. 3. Voshaar T et al. Comparing Usability of NEXThaler[1] with Other Inhaled Corticosteroid/Long-Acting b2-Agonist Fixed Combination Dry Powder Inhalers in Asthma Patients Journal of aerosol medicine and pulmonary drug delivery. Volume 27, 2014. Pp. 1-8. DOI: 10.1089/jamp.2013.1086. 4. Ficha técnica de Formodual® Nexthaler®. 5. Terzano C et al. 1-year prospective real life monitoring of asthma control and quality of life in Italy. Respir Res 2012 Dec 6;13:112. 6. Allegra L et al. Real-life prospective study on asthma control in Italy: cross-sectional phase results. Respir Med 2012;106:205-14. VER FICHA TÉCNICA |
|
No hay comentarios:
Publicar un comentario
Nota: solo los miembros de este blog pueden publicar comentarios.